Action Selvita - 0RKT

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

57,00

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

0,00

0,00 Fourchette du Jour 0,00

57,00 Plage de 52 semaines 57,00

Cap du marché

1,318B

Clôture Veille

57,00

Ouverture

Dernière Transaction

(O)

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

23 120 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-14,31

Bénéfice par action (BPA)

-3,98

Chiffre d'affairess

67,99M

Bénéfice net

-92,11M

Secteur

Chemicals & Chem Preps, Nec

Industrie

Chemicals & Chem Preps, Nec

Site Web

ryvu.com

Siège social

Krakow, Pol

Fondé

Selvita Sa est coté dans le secteur Chemicals & Chem Preps de la London Stock Exchange avec le ticker 0RKT. Le dernier cours de clôture d'Selvita était de PLN57,00. Au cours de la dernière année, les actions de Selvita ont été négociées dans une fourchette de prix de PLN 57,00 à PLN 57,00.

Selvita compte actuellement 23 120 000 actions en circulation. La capitalisation boursière d'Selvita est de PLN1,32 milliard. Selvita a un ratio cours/bénéfice (ratio PE) de -14.31.

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR...

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR...

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit PR Newswire KRAKOW, Poland, Sept. 23...

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress PR Newswire KRAKOW...

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting PR Newswire KRAKOW...

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with...

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting PR Newswire KRAKOW, Poland, Nov. 2...

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update PR Newswire KRAKOW, Poland, Sept. 28, 2022 KRAKOW...

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress PR...

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting PR Newswire KRAKOW, Poland, March 8, 2022 KRAKOW...

Période	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	57	57	57	0	0	DE
4	57	57	57	0	0	DE
12	57	57	57	1	57	DE
26	57	57	57	1	57	DE
52	57	57	57	0	57	DE
156	57	57	57	0	57	DE
260	57	57	57	0	57	DE

0RKT - Frequently Asked Questions (FAQ)

What is the current Selvita share price?

The current share price of Selvita is PLN 57,00

How many Selvita shares are in issue?

Selvita has 23 120 000 shares in issue

What is the market cap of Selvita?

The market capitalisation of Selvita is PLN 1,32B

What is the 1 year trading range for Selvita share price?

Selvita has traded in the range of PLN 57,00 to PLN 57,00 during the past year

What is the PE ratio of Selvita?

The price to earnings ratio of Selvita is -14,31

What is the cash to sales ratio of Selvita?

The cash to sales ratio of Selvita is 19,38

What is the reporting currency for Selvita?

Selvita reports financial results in PLN

What is the latest annual turnover for Selvita?

The latest annual turnover of Selvita is PLN 67,99M

What is the latest annual profit for Selvita?

The latest annual profit of Selvita is PLN -92,11M

What is the registered address of Selvita?

The registered address for Selvita is ST. LEONA HENRYKA STERNBACHA 2, KRAKOW, 30-394

What is the Selvita website address?

The website address for Selvita is ryvu.com

Which industry sector does Selvita operate in?

Selvita operates in the CHEMICALS & CHEM PREPS, NEC sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
AMGOAmigo Holdings Plc	0,475p (72,73%)	11,81M
BEMBeowulf Mining Plc	22,00p (25,71%)	104,2k
WSGWestminster Group Plc	1,30p (23,81%)	1,4M
BLOEBlock Energy Plc	1,00p (21,21%)	11,06M
SMLStrategic Minerals Plc	0,30p (20,00%)	11,23M
SSTScottish Oriental Smaller Companies Trust Plc	290,00p (-95,96%)	76,08k
ONCOncimmune Holdings Plc	1,40p (-43,78%)	1,57M
BMTOBraime Group Plc	1 350,00p (-20,59%)	547
PYXPyx Resources Limited	1,97p (-19,76%)	398,74k
MGAMMorgan Advanced Materials Plc	214,50p (-16,21%)	8,59M
TRPTower Resources Plc	0,0245p (6,52%)	775,51M
UKOGUk Oil & Gas Plc	0,01125p (-4,26%)	434,61M
TW.Taylor Wimpey Plc	114,25p (2,05%)	345,64M
LLOYLloyds Banking Group Plc	72,32p (0,84%)	344,78M
PREMPremier African Minerals Limited	0,0205p (-11,26%)	300,49M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Selvita Sa (0RKT)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Selvita Sa

0RKT Dernières nouvelles

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

0RKT - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	57	57	57	0	0	DE
4	57	57	57	0	0	DE
12	57	57	57	1	57	DE
26	57	57	57	1	57	DE
52	57	57	57	0	57	DE
156	57	57	57	0	57	DE
260	57	57	57	0	57	DE

Période	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	57	57	57	0	0	DE
4	57	57	57	0	0	DE
12	57	57	57	1	57	DE
26	57	57	57	1	57	DE
52	57	57	57	0	57	DE
156	57	57	57	0	57	DE
260	57	57	57	0	57	DE

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Selvita Sa (0RKT) Cours

Selvita Sa (0RKT)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Selvita Sa

0RKT Dernières nouvelles

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Ryvu Therapeutics to Present Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting

Ryvu Therapeutics Reports 2022 Half-Year Financial Results and Provides Corporate Update

Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2022 European Hematology Association (EHA) Congress

Ryvu Therapeutics to Present Data from its Oncology Programs at AACR 2022 Annual Meeting

Ryvu Therapeutics presents clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present clinical and preclinical data on RVU120, RVU305, and novel synthetic lethality programs at the 2024 EORTC-NCI-AACR Symposium

Ryvu Therapeutics to present ONCO Prime platform at the 6th Annual RAS-Targeted Drug Development Summit

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

0RKT - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	57	57	57	0	0	DE
4	57	57	57	0	0	DE
12	57	57	57	1	57	DE
26	57	57	57	1	57	DE
52	57	57	57	0	57	DE
156	57	57	57	0	57	DE
260	57	57	57	0	57	DE